Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

Fig. 1

IRF-1 assay validation in cell lines and melanoma cases. a Induction of IRF-1 and PD-L1 with increasing concentrations of interferon gamma in YUGEN and Mel624 melanoma cell lines by Western blot. b Induction of IRF-1 and PD-L1 in YUGEN melanoma cells by immunofluorescence. Green (Cy3 channel) = HMB45/S100 tumor mask. Red (Cy5 channel) = target

Back to article page